TABLE 2. Postnatal neuroimaging* and infant Zika virus testing results for 895 liveborn infants in the U.S. Zika Pregnancy Registry — 50 U.S. states and the District of Columbia, 2016.
| Testing | No (%) liveborn infants |
||
|---|---|---|---|
| With birth defects | Without birth defects | Total | |
|
Total
|
45
|
850
|
895
|
|
Neuroimaging
| |||
| Any neuroimaging reported to USZPR |
29 (64) |
192 (23) |
221 (25)
|
|
Infant Zika virus testing
| |||
| Positive test result on an infant specimen†,§ |
25 (56) |
69 (8) |
94 (11)
|
| Negative infant test results among infants with ≥1 infant specimen reported as tested |
17 (38) |
474 (56) |
491 (55)
|
| No infant specimen test results reported to USZPR | 3 (7) | 307 (36) | 310 (35) |
Abbreviations: IgM= immunoglobulin M; NAT=nucleic acid test; RT-PCR = reverse transcription–polymerase chain reaction; USZPR = U.S. Zika Pregnancy Registry.
* Neuroimaging includes any cranial ultrasound, computed tomography, or magnetic resonance imaging test reported to the USZPR.
† Positive infant tests included the presence of Zika virus RNA by a positive NAT (e.g., RT-PCR) and/or serological results of IgM positive/equivocal.
§ Infant specimens include serum, urine, blood, cerebrospinal fluid, cord serum, and cord blood.